Atrial Fibrillation Anticoagulation

Clinical Application & Nuances

1. Why NOACs Are Contraindicated in Rheumatic Valvular AF

• In India, Rheumatic Heart Disease (RHD) remains highly prevalent, though the incidence is reducing, so this branch is not a rare one here.
• The ICMR Standard Treatment Workflow on atrial fibrillation, revised January 2026, puts it in one line: a vitamin K antagonist only for severe mitral stenosis or a metallic valve, and a direct oral anticoagulant otherwise.
• The VKA / Warfarin Titration pathway sets the target INR and the dose adjustment.

2. Female Sex, and Why the Score Itself Changed in 2024

Female sex is a risk modifier, not an independent risk factor. In the absence of other CHA₂DS₂-VASc factors, a biological female scores a 1, but this does not confer significant stroke risk, and OAC is not recommended on this basis alone. Three current documents handle the point differently.

3. The R₂CHA₂DS₂-VASc Upgrade

Ticking the renal box adds 2 points for a creatinine clearance below 60 mL/min. Two things about where those points come from are worth knowing before the score is used to start a drug for life.

• What the derivation actually was. The 2 points are from R₂CHADS₂ (Piccini 2013), which added renal function to CHADS₂, not to CHA₂DS₂-VASc, and improved net reclassification by 6.2 per cent against CHA₂DS₂-VASc and by 8.2 per cent against CHADS₂. It was derived in ROCKET AF and validated in ATRIA, and ROCKET AF enrolled only patients with a CHADS₂ of 2 or more and a creatinine clearance of 30 or more. So the renal points were established in patients who were already at moderate to high risk. A patient whose only risk factor is a clearance below 60 was not in that cohort.
• The contrary evidence. Roldan and colleagues asked whether chronic kidney disease adds predictive information to CHADS₂ and CHA₂DS₂-VASc. In an anticoagulated outpatient cohort it did not. Renal function predicts a poor overall prognosis, but the risk factors already in the two scores carry the information.
• Neither the 2024 ESC guideline nor the 2023 ACC/AHA guideline scores renal function in the stroke risk assessment. This tool keeps the option and prints no annual rate for it, because no published rate table covers the modified score.
• Renal function is worth knowing for the anticoagulant dose whatever the stroke score says.

4. A High HAS-BLED Score Is Not a Reason to Withhold Anticoagulation

A high HAS-BLED score (≥ 3) should never be used in isolation to deny a patient OAC if their stroke risk is high. It should be used to flag the need for closer monitoring and to actively correct modifiable bleeding risks (e.g., optimising BP, stopping NSAIDs, reducing alcohol intake).

5. NOACs vs. Warfarin (VKA)

• NOACs (Apixaban, Rivaroxaban, Dabigatran): Recommended as first-line therapy over Warfarin in eligible (non-valvular) patients with AFib due to a significantly lower risk of intracranial haemorrhage and no need for routine INR monitoring.
• Renal Dosing: All NOACs require dose reduction in severe renal impairment. Dabigatran is heavily renally cleared and should be avoided in severe CKD; Apixaban is the preferred choice in advanced kidney disease.